The role of galectins‑1, 3, 7, 8 and 9 as potential diagnostic and therapeutic markers in ovarian cancer (Review)

Mielczarek‑Palacz,Aleksandra; Kondera‑Anasz,Zdzisława; Smycz‑Kubańska,Marta; Englisz,Aleksandra; Janusz,Aleksandra; Królewska‑Daszczyńska,Patrycja; Wendlocha,Dominika

doi:10.3892/mmr.2022.12682

The role of galectins‑1, 3, 7, 8 and 9 as potential diagnostic and therapeutic markers in ovarian cancer (Review)

Authors:
- Aleksandra Mielczarek‑Palacz
- Zdzisława Kondera‑Anasz
- Marta Smycz‑Kubańska
- Aleksandra Englisz
- Aleksandra Janusz
- Patrycja Królewska‑Daszczyńska
- Dominika Wendlocha
View Affiliations

Affiliations: Department of Immunology and Serology, School of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40‑055 Katowice, Poland
Published online on: March 15, 2022 https://doi.org/10.3892/mmr.2022.12682
Article Number: 166
Copyright: © Mielczarek‑Palacz et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of ovarian cancer is increasing, particularly throughout the highly developed countries, while this cancer type remains a major diagnostic and therapeutic challenge. The currently poorly recognized lectins called galectins have various roles in interactions occurring in the tumor microenvironment. Galectins are involved in tumor‑associated processes, including the promotion of growth, adhesion, angiogenesis and survival of tumor cells. Results of research studies performed so far point to a complex role of galectins‑1, 3, ‑7, ‑8 and ‑9 in carcinogenesis of ovarian cancer and elucidation of the mechanisms may contribute to novel forms of therapies targeting the proteins. In particular, it appears important to recognize the reasons for changes in expression of galectins. Galectins also appear to be a useful diagnostic and prognostic tool to evaluate tumor progression or the efficacy of therapies in patients with ovarian cancer, which requires further study.

View Figures

View References

1	Kossai M, Leary A, Scoazec JY and Genestie C: Ovarian cancer: A heterogeneous disease. Pathobiology. 85:41–49. 2018. View Article : Google Scholar : PubMed/NCBI
2	Kroeger PT and Drapkin R: Pathogenesis and heterogeneity in ovarian cancer. Curr Opin Obstet Gynecol. 29:26–34. 2017. View Article : Google Scholar : PubMed/NCBI
3	Labrie M, De Araujo LOF, Communal L, Mes-Masson AM and St-Pierre Y: Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers. Sci Rep. 7:13242017. View Article : Google Scholar : PubMed/NCBI
4	Dubé-Delarosbil C and St-Pierre Y: The emerging role of galectins in high-fatality cancers. Cell Mol Life Sci. 75:1215–1226. 2018. View Article : Google Scholar : PubMed/NCBI
5	Compagno D, Gentilini LD, Jaworski FM, Pérez IG, Contrufo G and Laderach DJ: Glycans and galectins in prostate cancer biology, angiogenesis and metastasis. Glycobiology. 24:899–906. 2014. View Article : Google Scholar : PubMed/NCBI
6	Thijssen VL, Rabinovich GA and Griffioen AW: Vascular galectins: Regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev. 24:547–558. 2013. View Article : Google Scholar : PubMed/NCBI
7	Dings RP, Miller MC, Griffin RJ and Mayo KH: Galectins as molecular targets for therapeutic intervention. Int J Mol Sci. 19:905–927. 2018. View Article : Google Scholar : PubMed/NCBI
8	Wdowiak K, Francuz T, Gallego-Colon E, Ruiz-Agamez N, Kubeczko M, Grochoła I and Wojnar J: Galectin targeted therapy in oncology: Current knowledge and perspectives. Int J Mol Sci. 19:210–231. 2018. View Article : Google Scholar : PubMed/NCBI
9	Balan V, Nangia-Makker P and Raz A: Galectins as cancer biomarkers. Cancers (Basel). 2:592–610. 2010. View Article : Google Scholar : PubMed/NCBI
10	Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT and Iacobelli S: Galectins and their ligands: Amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 23:313–320. 2002. View Article : Google Scholar : PubMed/NCBI
11	Camby I, Le Mercier M, Lefranc F and Kiss R: Galectin-1: A small protein with major functions. Glycobiology. 16:137R–157R. 2006. View Article : Google Scholar : PubMed/NCBI
12	Wu MH, Hong TM, Cheng HW, Pan SH, Liang YR, Hong HC, Chiang WF, Wong TY, Shieh DB, Shiau AL, et al: Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. Mol Cancer Res. 7:311–318. 2009. View Article : Google Scholar : PubMed/NCBI
13	Anginot A, Espeli M, Chasson L, Mancini SJ and Schiff C: Galectin1 modulates plasma cell homeostasis and regulates the humoral immune response. J Immunol. 190:5526–5533. 2013. View Article : Google Scholar : PubMed/NCBI
14	Sandberg TP, Oosting J, van Pelt G, Mesker WE, Tollenaar RAEM and Morreau H: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio-increased expression of galectin-1 in tumors with high stromal content. Oncotarget. 9:31502–31515. 2018. View Article : Google Scholar : PubMed/NCBI
15	Satelli A, Rao PS, Gupta PK, Lockman PR, Srivenugopal KS and Rao US: Varied expression and localization of multiple galectins in different cancer cell lines. Oncol Rep. 19:587–594. 2008.PubMed/NCBI
16	Hughes RC: Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta. 1473:172–185. 1999. View Article : Google Scholar : PubMed/NCBI
17	Sundblad V, Morosi LG, Geffner JR and Rabinovich GA: Galectin-1: A Jack-of-All-Trades in the resolution of acute and chronic inflammation. J Immunol. 199:3721–3730. 2017. View Article : Google Scholar : PubMed/NCBI
18	Perillo NL, Pace KE, Seilhamer JJ and Baum LG: Apoptosis of T cells mediated by galectin-1. Nature. 378:736–739. 1995. View Article : Google Scholar : PubMed/NCBI
19	Rabinovich GA, Iglesias MM, Modesti NM, Castagna LF, Wolfenstein-Todel C, Riera CM and Sotomayor CE: Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells: Biochemical and functional characterization. J Immunol. 160:4831–4840. 1998.PubMed/NCBI
20	Matarrese P, Tinari A, Mormone E, Bianco GA, Toscano MA, Ascione B, Rabinovich GA and Malorni W: Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem. 280:6969–6985. 2005. View Article : Google Scholar : PubMed/NCBI
21	Dias-Baruffi M, Zhu H, Cho M, Karmakar S, McEver RP and Cummings RD: Dimeric galectin-1 induces surface exposure of phosphatidylserine and phagocytic recognition of leukocytes without inducing apoptosis. J Biol Chem. 278:41282–41293. 2003. View Article : Google Scholar : PubMed/NCBI
22	Stowell SR, Karmakar S, Stowell CJ, Dias-Baruffi M, McEver RP and Cummings RD: Human galectins-1, −2, and −4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood. 109:219–227. 2007. View Article : Google Scholar : PubMed/NCBI
23	Hernandez JD and Baum LG: Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology. 12:127–136. 2002. View Article : Google Scholar : PubMed/NCBI
24	Sturm A, Lensch M and Andre S: Human galectin-2: Novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol. 173:3825–3837. 2004. View Article : Google Scholar : PubMed/NCBI
25	Fuertes MB, Molinero LL, Toscano MA, Ilarregui JM, Rubinstein N, Fainboim L, Zwirner NW and Rabinovich GA: Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase. Mol Cell Biochem. 267:177–185. 2004. View Article : Google Scholar : PubMed/NCBI
26	Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL and Rabinovich GA: Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: A potential mechanism of tumor-immune privilege. Cancer Cell. 5:241–251. 2004. View Article : Google Scholar : PubMed/NCBI
27	Toscano MA, Commodaro AG, Ilarregui JM, Bianco GA, Liberman A, Serra HM, Hirabayashi J, Rizzo LV and Rabinovich GA: Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J Immunol. 176:6323–6332. 2006. View Article : Google Scholar : PubMed/NCBI
28	Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD, Zwirner NW, Poirier F, Riley EM, Baum LG and Rabinovich GA: Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol. 8:825–834. 2007. View Article : Google Scholar : PubMed/NCBI
29	Kuo PL, Huang MS, Cheng DE, Hung JY, Yang CJ and Chou SH: Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor. J Biol Chem. 287:9753–9764. 2012. View Article : Google Scholar : PubMed/NCBI
30	Soldati R, Berger E, Zenclussen AC, Jorch G, Lode HN, Salatino M, Rabinovich GA and Fest S: Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int J Cancer. 131:1131–1141. 2012. View Article : Google Scholar : PubMed/NCBI
31	Ilarregui JM, Croci DO, Bianco GA, Toscano MA, Salatino M, Vermeulen ME, Geffner JR and Rabinovich GA: Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol. 10:981–991. 2009. View Article : Google Scholar : PubMed/NCBI
32	Cedeno-Laurent F, Opperman M, Barthel SR, Kuchroo VK and Dimitroff CJ: Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol. 188:3127–3137. 2012. View Article : Google Scholar : PubMed/NCBI
33	Baatar D, Olkhanud PB, Wells V, Indig FE, Mallucci L and Biragyn A: Tregs utilize beta-galactoside-binding protein to transiently inhibit PI3K/p21ras activity of human CD8⁺ T cells to block their TCR-mediated ERK activity and proliferation. Brain Behav Immun. 23:1028–1037. 2009. View Article : Google Scholar : PubMed/NCBI
34	Garín MI, Chu CC, Golshayan D, Cernuda-Morollón E, Wait R and Lechler RI: Galectin-1: A key effector of regulation mediated by CD4⁺CD25⁺ T cells. Blood. 109:2058–2065. 2007. View Article : Google Scholar : PubMed/NCBI
35	Espeli M, Mancini SJ, Breton C, Poirier F and Schiff C: Impaired B-cell development at the pre-BII-cell stage in galectin-1-deficient mice due to inefficient pre-BII/stromal cell interactions. Blood. 113:5878–5886. 2009. View Article : Google Scholar : PubMed/NCBI
36	Mourcin F, Breton C, Tellier J, Narang P, Chasson L, Jorquera A, Coles M, Schiff C and Mancini SJ: Galectin-1-expressing stromal cells constitute a specific niche for pre-BII cell development in mouse bone marrow. Blood. 117:6552–6561. 2011. View Article : Google Scholar : PubMed/NCBI
37	Tsai CM, Chiu YK, Hsu TL, Lin IY, Hsieh SL and Lin KI: Galectin-1 promotes immunoglobulin production during plasma cell differentiation. J Immunol. 181:4570–4579. 2008. View Article : Google Scholar : PubMed/NCBI
38	Chen L, Yao Y, Sun L and Tang J: Galectin-1 promotes tumor progression via NF-κB signaling pathway in epithelial ovarian cancer. J Cancer. 8:3733–3741. 2017. View Article : Google Scholar : PubMed/NCBI
39	Zhang P, Shi B, Zhou M, Jiang H, Zhang H, Pan X, Gao H, Sun H and Li Z: Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis. 5:e9912014. View Article : Google Scholar : PubMed/NCBI
40	Kim HJ, Jeon HK, Cho YJ, Park YA, Choi JJ, Do IG, Song SY, Lee YY, Choi CH, Kim TJ, et al: High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer. 48:1914–1921. 2012. View Article : Google Scholar : PubMed/NCBI
41	Schulz H, Schmoeckel E, Kuhn C, Hofmann S, Mayr D, Mahner S and Jeschke U: Galectins-1, −3, and −7 are prognostic markers for survival of ovarian cancer patients. Int J Mol Sci. 18:12302017. View Article : Google Scholar : PubMed/NCBI
42	Chen L, Yao Y, Sun L, Zhou J, Liu J, Wang J, Li J and Tang J: Clinical implication of the serum galectin-1 expression in epithelial ovarian cancer patients. J Ovarian Res. 8:782015. View Article : Google Scholar : PubMed/NCBI
43	Abdelwahab M, Ebian H, Ibrahim T, Badr M, Lashin M, Yassin M, Ismail A and Obaya A: Clinical significance of serum galectin-1 and its tissue immunohistochemical expression in serous ovarian carcinoma patients. J Obstet Gynecol. 9:937–953. 2019.
44	Argüeso P and Panjwani N: Focus on molecules: Galectin-3. Exp Eye Res. 9:2–3. 2011. View Article : Google Scholar : PubMed/NCBI
45	Pinnelli V, Sirsiker M and Silvia WD: Galectin-3: A novel biomarker. Int J Chem Pharm Res. 2:81–94. 2013.
46	Lityńska A and Pokrywka M: Structure and biological functions of galectin-3 Część Part I. Post Biol Kom. 37:677–684. 2010.
47	Pokrywka M and Lityńska A: Structure and biological functions of galectin-3 Part II. Post Biol Kom. 37:685–697. 2010.
48	Ruvolo P: Galectin-3 as a guardian of the tumor microenvironment. Biochim Biophys Acta. 1863:427–437. 2016. View Article : Google Scholar : PubMed/NCBI
49	Gudowska M and Chrostek L: Diagnostic role of galectin-3. Pol Merkur Lekarski. 222:408–412. 2014.(In Polish). PubMed/NCBI
50	Li M, Feng YM and Fang SQ: Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer. Braz J Med Biol Res. 50:5356–5365. 2017. View Article : Google Scholar
51	Wdowiak K, Spychałowicz W, Fajkis M and Wojnar J: Galectins in hematological malignancies-role, functions and potential therapeutic targets. Postepy Hig Med Dosw (Online. 70:95–103. 2016.(In Polish). View Article : Google Scholar : PubMed/NCBI
52	Punt S, Thijssen VL, Vrolijk J, de Kroon CD, Gorter A and Jordanova E: Galectin-1, −3 and −9 expression and clinical significance in squamous cervical cancer. PLoS One. 10:e01291192015. View Article : Google Scholar : PubMed/NCBI
53	Vladoiu MC, Labrie M and St-Pierre Y: Intracellular galectins in cancer cells: Potential new targets for therapy (Review). Int J Oncol. 44:1001–10014. 2014. View Article : Google Scholar : PubMed/NCBI
54	Chetry M, Thapa S, Hu X, Song Y, Zhang J, Zhu H and Zhu X: The role of galectins in tumor progression, treatment and prognosis of gynecological cancers. J Cancer. 9:4742–4755. 2018. View Article : Google Scholar : PubMed/NCBI
55	Wang L, Zhao Y, Wang Y and Wu X: The role of galectins in cervical cancer biology and progression. Biomed Res Int. 2018:21759272018.PubMed/NCBI
56	Farhad M, Rolig A and Redmond W: The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology. 7:e14344672018. View Article : Google Scholar : PubMed/NCBI
57	Lee JH, Zhang X, Shin BK, Lee ES and Kim I: Mac-2 binding protein and galectin-3 expression in mucinous tumors of the ovary: An annealing control primer system and immunohistochemical study. Pathology. 41:229–233. 2009. View Article : Google Scholar : PubMed/NCBI
58	Kim MK, Sung CO, Do IG, Jeon HK, Song TJ, Park HS, Lee YY, Kim BG, Lee JW and Bae DS: Overexpression of galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol. 16:352–358. 2011. View Article : Google Scholar : PubMed/NCBI
59	Brustmann H: Epidermal growth factor receptor expression in serous ovarian carcinoma: An immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol. 27:380–389. 2008. View Article : Google Scholar : PubMed/NCBI
60	Lu H, Liu Y, Wang D, Wang L, Zhou H, Xu G, Xie L, Wu M, Lin Z and Yu Y: Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway. Tumour Biol. 37:11469–11477. 2016. View Article : Google Scholar : PubMed/NCBI
61	Kang HG, Kim DH, Kim SJ, Cho Y, Jung J, Jang W and Chun KH: Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. Oncotarget. 7:68229–68241. 2016. View Article : Google Scholar : PubMed/NCBI
62	Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL and Nguyen DD: Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecol Oncol. 135:573–579. 2014. View Article : Google Scholar : PubMed/NCBI
63	Eliaz I: The role of galectin-3 as a marker of cancer and inflammation in a stage IV ovarian cancer patient with underlying pro-inflammatory comorbidities. Case Rep Oncol. 6:343–349. 2013. View Article : Google Scholar : PubMed/NCBI
64	Hossein G, Keshavarz M, Ahmadi S and Naderi N: Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev. 14:7561–7568. 2013. View Article : Google Scholar : PubMed/NCBI
65	Hossein G, Halvaei S, Heidarian Y, Dehghani-Ghobadi Z, Hassani M, Hosseini H, Naderi N and Sheikh Hassani S: Pectasol-C modified citrus pectin targets galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids. Cancer Med. 8:4315–4329. 2019. View Article : Google Scholar : PubMed/NCBI
66	Cai G, Ma X, Chen B, Huang Y, Liu S, Yang H and Zo W: Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signalingactivation. Tumour Biol. 37:11883–11891. 2016. View Article : Google Scholar : PubMed/NCBI
67	Wang D, You D and Li L: Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function. J Toxicol Sci. 44:47–56. 2019. View Article : Google Scholar : PubMed/NCBI
68	Bieg D, Sypniewski D, Nowak E and Bednarek I: Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Arch Gynecol Obstet. 298:1181–1194. 2018. View Article : Google Scholar : PubMed/NCBI
69	Bieg D, Sypniewski D, Nowak E and Bednarek I: MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Arch Gynecol Obstet. 299:1077–1087. 2019. View Article : Google Scholar : PubMed/NCBI
70	Kaur M, Kaur T, Kamboj S and Singh J: Roles of galectin-7 in cancer. Asian Pac J Cancer Prev. 17:455–461. 2016. View Article : Google Scholar : PubMed/NCBI
71	Menkhorst E, Griffiths M, van Sinderen M, Rainczuk K, Niven K and Dimitriadis E: Galectin-7 is elevated in endometrioid (type I) endometrial cancer and promotes cell migration. Oncol Lett. 16:4721–4728. 2018.PubMed/NCBI
72	Chou F, Chen H, Kuo C and Sytwu H: Role of galectins in tumors and in clinical immunotherapy. Int J Mol Sci. 19:430–441. 2018. View Article : Google Scholar : PubMed/NCBI
73	Johannes L, Jacob R and Leffler H: Galectins at a glance. J Cell Sci. 131:jcs2088842018. View Article : Google Scholar : PubMed/NCBI
74	Labrie M, Vladoiu MC, Grosset A, Gaboury L and St-Pierre Y: Expression and functions of galectin-7 in ovarian cancer. Oncotarget. 5:7705–7721. 2014. View Article : Google Scholar : PubMed/NCBI
75	Higareda-Almaraz JC, Ruiz-Moreno JS, Klimentova J, Barbieri D, Salvador-Gallego R, Ly R, Valtierra-Gutierrez IA, Dinsart C, Rabinovich GA, Stulik J, et al: Systems-level effects of ectopic galectin-7 reconstitution in cervical cancer and its microenvironment. BMC Cancer. 16:680–692. 2016. View Article : Google Scholar : PubMed/NCBI
76	St-Pierre Y: Towards a better understanding of the relationships between Galectin-7, p53 and MMP-9 during cancer progression. Biomolecules. 11:8792021. View Article : Google Scholar : PubMed/NCBI
77	Guo JP and Li XG: Galectin-7 promotes the invasiveness of human oral squamous cell carcinoma cells via activation of ERK and JNK signaling. Oncol Lett. 13:1919–1924. 2017. View Article : Google Scholar : PubMed/NCBI
78	Krześlak A: Akt kinase: A key regulator of metabolism and progression of tumors. Postepy Hig Med Dosw (Online). 64:490–503. 2010.(In Polish). PubMed/NCBI
79	Kim HJ, Jeon HK, Lee JK, Sung CO, Do IG, Choi CH, Kim TJ, Kim BG, Bae DS and Lee JW: Clinical significance of galectin-7 in epithelial ovarian cancer. Anticancer Res. 33:1555–1561. 2013.PubMed/NCBI
80	Bibens-Laulan N and St-Pierre Y: Intracellular galectin-7 expression in cancer cells results from an autocrine transcriptional mechanism and endocytosis of extracellular galectin-7. PLoS One. 12:e01871942017. View Article : Google Scholar : PubMed/NCBI
81	Elola MT, Ferragut F, Cárdenas Delgado VM, Nugnes LG, Gentilini L, Laderach D, Troncoso MF, Compagno D, Wolfenstein-Todel C and Rabinovich GA: Expression, localization and function of galectin-8, a tandem-repeat lectin, in human tumors. Histol Histopathol. 29:1093–1105. 2014.PubMed/NCBI
82	Zick Y, Eisenstein M, Goren RA, Hadari YR, Levy Y and Ronen D: Role of galectin-8 as a modulator of cell adhesion and cell growth. Glycoconj J. 19:517–526. 2002. View Article : Google Scholar : PubMed/NCBI
83	Troncoso MF, Ferragut F, Bacigalupo ML, Cárdenas Delgado VM, Nugnes LG, Gentilini L, Laderach D, Wolfenstein-Todel C, Compagno D, Rabinovich GA and Elola MT: Galectin-8: A matricellular lectin with key roles in angiogenesis. Glycobiology. 10:907–914. 2014. View Article : Google Scholar : PubMed/NCBI
84	Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR and Rabinovich GA: Galectins: Matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci. 64:1679–1700. 2007. View Article : Google Scholar : PubMed/NCBI
85	Levy Y, Arbel-Goren R, Hadari YR, Eshhar S, Ronen D, Elhanany E, Geiger B and Zick Y: Galectin-8 functions as a matricellular modulator of cell adhesion. J Biol Chem. 276:31285–31295. 2001. View Article : Google Scholar : PubMed/NCBI
86	Troncoso MF, Elola MT, Croci DO and Rabinovich GA: Integrating structure and function of ‘tandem-repeat’ galectins. Front Biosci (Schol Ed). 4:864–887. 2012.PubMed/NCBI
87	Tribulatti MV, Carabelli J, Prato CA and Campetella O: Galectin-8 in the onset of the immune response and inflammation. Glycobiology. 30:134–142. 2020. View Article : Google Scholar : PubMed/NCBI
88	Ferragut F, Cagnoni AJ, Colombo LL, Sánchez Terrero C, Wolfenstein-Todel C, Troncoso MF, Vanzulli SI, Rabinovich GA, Mariño KV and Elola MT: Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth. Biochim Biophys Acta Mol Cell Res. 1866:1338–1352. 2019. View Article : Google Scholar : PubMed/NCBI
89	Fan J, Tang X, Wang Q, Zhang Z, Wu S, Li W, Liu S, Yao G, Chen H and Sun L: Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9. Stem Cell Res Ther. 9:237–349. 2018. View Article : Google Scholar : PubMed/NCBI
90	Zhou X, Sun L, Jing D, Xu G, Zhang J, Lin L, Zhao J, Yao Z and Lin H: Galectin-9 expression predicts favorable clinical outcome in solid tumors: A systematic review and meta-analysis. Front Physiol. 9:4522018. View Article : Google Scholar : PubMed/NCBI
91	Fujihara S, Mori H, Kobara H, Rafiq K, Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy. Recent Pat Endocr Metab Immune Drug Discov. 7:130–137. 2013. View Article : Google Scholar : PubMed/NCBI
92	Lahm H, André S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, Wolf E and Gabius HJ: Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol. 127:375–386. 2001. View Article : Google Scholar : PubMed/NCBI